<DOC>
	<DOCNO>NCT01241643</DOCNO>
	<brief_summary>This Phase II multicenter , open-labeled , control , randomize study assess weekly dos Interleukin-7 ( CYT107 )</brief_summary>
	<brief_title>Randomized Study Multiple Cycles Interleukin-7 HIV Patients Immune Non-responders</brief_title>
	<detailed_description>The aim study ass repeat cycle 3 weekly injection CYT107 patient immune non-responders infect HIV . Eighty patient recruit study biological activity safety repeat cycle CYT107 20 µg/kg/week 2 week , maximum 4 cycle within 21 month maximum 3 cycle within 12 month . The entire study cover period 24 month . During study visit follow may do : - medical history , physical examination , blood test every visit - EKG - chest X-Ray - liver/spleen ultrasound</detailed_description>
	<criteria>1 . HIV1 infection document licensed ELISA ( EnzymeLinked Immunosorbent Assay ) test kit confirm either Western Blot 2nd test use different method time prior study entry 2 . Age ≥18 3 . On HAART ( Highly active antiretroviral therapy ) least 24 month , stable regimen least 6 month prior study entry . HAART define combination two ( 2 ) class dose regimen approve ARV ( antiretroviral ) 4 . CD4+ cell count ≥ 101 &lt; 350 cells/µL measure least two ( 2 ) measurement ( include screen value ) within previous 12 month prior study entry Note : single isolated value CD4+ ≥ 350 period ( 12 month prior study entry ) allow participate previous subsequent CD4+ count range ≥ 101 &lt; 350 cells/µL 5 . Plasma HIV RNA &lt; 50 copies/mL since least 18 month least two ( 2 ) measurement ( include screen value ) within previous 6 month prior study entry Note : patient single blip detectable viremia period ( 6 month prior study entry ) allow participate prior subsequent plasma HIV RNA level &lt; 50 copies/mL 6 . Adequate bone marrow , hepatic renal function follow : Hemoglobin ≥ 10 g/dl Neutrophils ≥ 1,000/µL Platelets ≥ 100,000/µL AST , ALT , Alk . Phosph . ≤ 2.5 x ULN Total Bilirubin ≤ 1.5 x ULN ( ≤ 5 x ULN patient treat atazanavir indinavir , increase due unconjugated bilirubin ALT AST normal ) Lipase ≤ 2 x ULN PT/PTT ≤ 1.5 x ULN Estimated glomerular filtration ≥ 60 ml/min ( accord MDRD formula ) 7 . Normal blood ThyroidStimulating Hormone ( TSH ) 8 . Ability understand sign inform consent 1 . AIDSdefining illness ( category C ) diagnose within last 12 month prior study entry 2 . History HIV relate encephalopathy 3 . Active opportunistic infection include active tuberculosis 4 . Previous treatment IL2 IL7 time prior study entry 5 . Any planned probable modification antiretroviral treatment first year first two cycle CYT107 Note : case product shortage absence viral mutation suspicion viral blip , modification ARV exclusion criterion 6 . Poor compliance HAART chronic treatment opinion investigator interfere protocol participation 7 . Previous treatment immunomodulatory agent , systemic corticosteroid , growth factor , immunosuppressive drug , HIV vaccine , anticancer treatment hydroxyurea within 3 month prior study entry 8 . Any history malignancy ( except basal carcinoma skin ) include hematologic malignancy AIDS defining malignancy , lymphoproliferative disorder Kaposi 's sarcoma Note : Patients Kaposi 's sarcoma limit skin disappear HAART therapy , without require systemic therapy 1 year prior study entry , eligible . 9 . Any history severe autoimmune disease require systemic treatment hospitalization , active autoimmune disease require treatment ( include multiple sclerosis ) 10 . History splenectomy 11 . Any hematologic disease associate hypersplenism , thalassemia , hereditary spherocytosis , Gaucher 's Disease , autoimmune hemolytic anemia 12 . Chronic hepatitis B C 13 . HIV2 , HTLV1 HTLV2 seropositivity 14 . Cirrhosis origin , alcoholic non alcoholic steatohepatitis , either prove histologically suspected 15 . Hypertension rest systolic blood pressure &gt; 140 rest diastolic blood pressure &gt; 90 mm despite adequate antihypertensive treatment 16 . Any cardiac , pulmonary , thyroid , renal , hepatic , gastrointestinal , neurological ( central peripheral ) disease require therapy consider significant investigator severe disorder hemostasis 17 . Any serious illness require systemic treatment and/or hospitalization patient either complete therapy clinically stable therapy , opinion principal investigator , least 30 day prior study entry 18 . Pregnant lactating woman . Women childbearing potential must negative serum urine pregnancy test study entry 19 . Refusal inability practice contraception regardless gender patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>interleukin-7</keyword>
	<keyword>immune-based therapy</keyword>
	<keyword>HIV</keyword>
	<keyword>infectious disease</keyword>
	<keyword>immune non-responders</keyword>
</DOC>